TAYLOR RIGGINS: Open Payments
NPI 1366224669 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,022 in 59 payments from 10 companies in 2025. Trend: 2023 $46 · 2024 $994 · 2025 $1,022
Food & beverage: $910Education: $111
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $276 |
| ABBVIE INC. | 14 | $194 |
| Teva Pharmaceuticals USA, Inc. | 7 | $178 |
| Otsuka America Pharmaceutical, Inc. | 12 | $143 |
| Neurocrine BioSciences, Inc. | 5 | $94 |
| Vanda Pharmaceuticals Inc. | 2 | $49 |
| Janssen Pharmaceuticals, Inc | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $16 |
Products named: ARISTADA, VRAYLAR, ABILIFY ASIMTUFII, INGREZZA, FANAPT, REXULTI, UZEDY, AUSTEDO XR.
Industry payments across MO — which companies pay providers there.
